CRANBURY, N.J., July 28 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. announced today the appointment of Steven Fischkoff, M.D. to the position of Vice President of Clinical Development. Dr. Fischkoff has 15 years of experience in the pharmaceutical industry and comes to Palatin Technologies from Medarex, where, most recently he held the position of Vice President of Clinical Science.
“We are extremely pleased to have Dr. Fischkoff join our management team,” stated Carl Spana, Ph.D., President and CEO of Palatin Technologies. “Dr. Fischkoff brings a broad range of clinical, management and regulatory experience to Palatin and will play an important role in our growth through his leadership of the clinical development of bremelanotide and our earlier pipeline programs.”
In his new position, Dr. Fischkoff will be responsible for directing the clinical development function encompassing the identification and implementation of clinical program strategies and overseeing the execution of clinical trials, data collection and interpretation and reporting of results. He will report to Trevor Hallam, Ph.D., Executive Vice President of Research & Development.
Dr. Fischkoff stated, “I am excited to join the Palatin organization and look forward to applying my skill sets and contributing to the development and advancement of the company’s clinical programs.”
Dr. Fischkoff received his M.D. degree from the University of Pennsylvania and has 15 years of domestic and international clinical development management experience in the pharmaceutical industry. Prior to his tenure at Medarex, he held the position of Senior Director Oncology/Immunology with Knoll Pharmaceuticals/Abbott Laboratories. Additionally, Dr. Fischkoff has spent 15 years in academic positions with the NYU School of Medicine, National Institutes of Health, University of Maryland School of Medicine and University of Pennsylvania School of Medicine.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company primarily engaged in the development of melanocortin-based therapeutics. The Company’s lead product candidate, bremelanotide, is currently in Phase II clinical trials for both male and female sexual dysfunction. The Company’s internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, the Company has formed partnerships with Tyco Healthcare Mallinckrodt and King Pharmaceuticals. For additional information regarding Palatin, please visit Palatin Technologies’ website at http://www.palatin.com.
Forward-looking Statements
Statements about the Company’s future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to the Company’s ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre- clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R) and ability to protect its intellectual property, and other factors discussed in the Company’s periodic filings with the Securities and Exchange Commission. The Company is not responsible for updating for events that occur after the date of this press release.
Palatin Technologies, Inc.
CONTACT: For Palatin Technologies: Stephen T. Wills, CPA, MST,EVP-Operations / Chief Financial Officer, +1-609-495-2200,info@palatin.com; or For Institutional Investors and Media: Carney Duntsch,Burns McClellan, +1-212-213-0006, cduntsch@burnsmc.com
Web site: http://www.palatin.com/
